Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dynon M. K., Jarrott B., Drummer O., Louis W. J. Pharmacokinetics of prazosin in normotensive subjects after low oral doses. Clin Pharmacokinet. 1980 Nov-Dec;5(6):583–590. doi: 10.2165/00003088-198005060-00007. [DOI] [PubMed] [Google Scholar]
- Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate Suppl. 1990;3:75–84. doi: 10.1002/pros.2990170508. [DOI] [PubMed] [Google Scholar]
- Magorien R. D., Sinnathamby S., Leier C. V., Boudoulas H., Unverferth D. V. Rest and exercise cardiovascular effects of terazosin in congestive heart failure. Am J Cardiol. 1990 Mar 1;65(9):638–643. doi: 10.1016/0002-9149(90)91044-7. [DOI] [PubMed] [Google Scholar]
- McNeil J. J., Drummer O. H., Conway E. L., Workman B. S., Louis W. J. Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin. J Cardiovasc Pharmacol. 1987 Aug;10(2):168–175. doi: 10.1097/00005344-198708000-00006. [DOI] [PubMed] [Google Scholar]
- Pool J. L., Nelson E. B., Taylor A. A., Mitchell J. R. Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension. Br J Clin Pract Suppl. 1987 Dec;54:9–14. [PubMed] [Google Scholar]
- Sonders R. C. Pharmacokinetics of terazosin. Am J Med. 1986 May 23;80(5B):20–24. doi: 10.1016/0002-9343(86)90847-8. [DOI] [PubMed] [Google Scholar]